Mirikizumab for Crohn's Disease

(MIRIAD Trial)

This trial aims to test the safety and effectiveness of mirikizumab, a treatment for Crohn's disease, specifically for people with strictures (narrowed sections) in the intestines. Participants will receive mirikizumab through a series of injections to determine if it helps manage their symptoms and improves their condition. It suits adults who have had Crohn's disease affecting their ileum (part of the small intestine) for at least three months, experience abdominal pain after eating, and have certain types of intestinal narrowing. As a Phase 4 trial, this research seeks to understand how this already FDA-approved and effective treatment can benefit more patients.

Participants can continue taking certain medications for Crohn's Disease, like oral 5-ASA drugs, sulfasalazine, AZA, 6-MP, MTX, rectal therapies, antidiarrheal drugs, and bile acid sequestrants, as long as they have been stable for a specified period before the trial. However, some medications like cyclosporine, tacrolimus, and certain biologics must be stopped before the trial. Participants on corticosteroids must be willing to taper off after 8 weeks.

Research has shown that mirikizumab is generally safe for people with Crohn's disease. Studies have found that patients can use mirikizumab safely for extended periods, with many experiencing significant improvements. Specifically, using mirikizumab for up to 104 weeks helped heal the gut and control symptoms effectively. Safety data over several years indicate that patients often remain in remission without needing steroids, which supports its safety. Overall, mirikizumab has a positive safety record for treating moderate-to-severe Crohn's disease, with no major safety issues reported in the studies.¹²³⁴⁵

Mirikizumab is unique because it targets the p19 subunit of interleukin-23, a protein involved in inflammation, which is different from many existing Crohn's disease treatments that target other inflammatory pathways, like TNF inhibitors. Researchers are excited about Mirikizumab because it offers a new mechanism of action, potentially providing relief for patients who do not respond well to current therapies. Additionally, its administration starts with an intravenous dose and transitions to a subcutaneous form, which can offer both rapid initial relief and convenient ongoing treatment.

Research has shown that mirikizumab can help treat Crohn's disease. In some studies, up to 96% of patients experienced significant symptom improvement, and about 87% saw their symptoms become minimal or disappear. Another study found that 60.5% to 67.1% of patients showed improvement in intestinal inflammation. These findings suggest that mirikizumab could be a promising option for effectively managing Crohn's disease symptoms.¹²³⁶⁷